An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A review of ten years of reports to the FDA’s adverse event database (called FAERS) found signals that two popular diabetes and weight-loss drugs — semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (Zepbound for weight loss, Mounjaro for diabetes) — may be linked to cases of hair loss (alopecia). In plain terms, researchers looked at a big pile of voluntary reports from patients and doctors and noticed more mentions of hair loss with these drugs than you might expect compared with other medicines. Semaglutide is a man-made version of a gut hormone that helps control blood sugar and reduces appetite by telling the brain you’re full and slowing stomach emptying. Tirzepatide is newer and acts like two gut hormones at once, with similar effects on appetite and blood sugar. Both are injectable medicines used for type 2 diabetes and, at higher doses, for chronic weight management. They’re not “hair drugs” — their main job is to affect metabolism, but because they change appetite and weight, people on them can experience a range of other effects. The FAERS review is not a controlled experiment. It’s an analysis of reports submitted over ten years, many of them voluntary. These reports suggested a higher-than-expected number of hair-loss cases linked to semaglutide and tirzepatide compared with other drugs in the database. That kind of signal can mean there’s something worth investigating, but it does not prove the drugs caused the hair loss. The review didn’t measure how often hair loss happens overall, didn’t confirm diagnoses, and can’t fully account for other reasons someone might lose hair, like stress, nutritional changes, rapid weight loss, or other medications. Why this matters is practical. Semaglutide and tirzepatide are being used by more people for weight loss than ever before. Hair loss is an obvious and sometimes distressing side effect for many people, and even if it’s rare, it could affect treatment choices. If you’re starting one of these medicines, or already on one and notice thinning or shedding, it’s reasonable to bring it up with your prescriber. They can check for other causes and help decide whether to adjust treatment. There are important caveats. FAERS is a signal-detection tool, not proof of cause. Hair loss can have many causes, and voluntary reports can be biased (people are more likely to report unusual or concerning effects). These drugs have known side effects like nausea, gastrointestinal upset, and changes in appetite; hair loss has not been established as a clear, common effect. Also, regulatory agencies will need controlled studies or well-designed epidemiologic research to confirm a link. If you have a history of hair disorders, are pregnant, or have other health issues, discuss risks with your doctor before starting these medicines. Bottom line: a large review of voluntary FDA reports flagged possible links between semaglutide and tirzepatide and hair loss, which is worth attention but not proof — talk to your clinician if you notice changes and watch for more research.
Source: Dermatology Times